Agios Pharmaceuticals Inc. reported its fourth quarter (Q4) and full year (FY) 2025 financial results, highlighting robust commercial performance and continued advancement of its product portfolio. In Q4 2025, Agios posted US net revenues of USD 16.0 million and ex-US net revenues of USD 4.0 million, driven by increased patient demand for PYRUKYND in pyruvate kinase $(PK)$ deficiency and stocking ahead of anticipated demand in Europe. For the full year 2025, US net revenues reached USD 49.2 million, while ex-US net revenues totaled USD 4.8 million. FY 2025 net revenues grew 48 percent compared to FY 2024, reflecting strong commercial execution. Cost of sales in Q4 2025 was USD 1.9 million, with research and development expenses at USD 88.1 million and selling, general, and administrative expenses at USD 51.6 million. The company reported a net loss of USD 108.0 million for the quarter and USD 412.8 million for the full year 2025. As of Q4 2025, Agios held cash, cash equivalents, and marketable securities totaling USD 1.2 billion. On the commercial front, Agios reported encouraging initial demand for AAVESME (mitapivat) in thalassemia, recording 44 prescriptions from FDA approval on 23 December 2025 through 30 January 2026, primarily driven by community physicians and transfusion-dependent patients. The company outlined strategic priorities for 2026, including maximizing the launch of AAVESME in thalassemia, expanding its PK activation franchise into sickle cell disease, and refining its operating model to drive efficiencies. Agios anticipates operating expenses in 2026 to remain flat compared to 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.